logo

For the Inventor, By the Inventor

Philadelphia, PA, United States of America

Siegfried B Christensen, Iv

USPTO Granted Patents = 63

Average Co-Inventor Count = 2.5

ph-index = 12

Forward Citations = 451(Granted Patents)

Forward Citations (Not Self Cited) = 409(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Philadelphia, PA (US) (1995 - 2003)
  • King of Prussia, PA (US) (1994 - 2006)
  • Collegeville, PA (US) (2003 - 2016)

Company Filing History:

goldMedal60 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal1 out of 1,168 
 
Glaxo Group Limited
 patents
bronzeMedal1 out of 1 
 
Smithkline Beecham Pharma Gmbh
 patent
4. 1 out of 95 
 
Glaxosmithkline Intellectual Property (no.2) Limited
 patents
5. 1 out of 356 
 
Glaxosmithkline LLC
 patents
where one patent can have more than one assignee

Years Active: 1994-2016

Loading Chart...
Areas of Expertise:
Diacylglycerol Acyltransferase Inhibitors
Peptide Deformylase Inhibitors
PDE4 Inhibitors
Fatty Acid Synthase Inhibitors
Cannabinoid Receptor Modulators
Anti-Inflammatory Treatments
Cyclohexane Monomers
Allergic Disease Treatments
Inflammation Treatments
Aryl Difluoromethyl Ethers
Exercise Induced Asthma Treatments
COPD Treatments
63 patents (USPTO):Explore Patents
1. 9242929 - Compounds as diacylglycerol acyltransferase inhibitors (2016-01-26),
2. 7919528 - Peptide deformylase inhibitors (2011-04-05),
3. 7709497 - Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor (2010-05-04),
4. 7507726 - Peptide deformylase inhibitors (2009-03-24),
5. 7456211 - Peptide deformylase inhibitors (2008-11-25),
6. 7442793 - Peptide deformylase inhibitors (2008-10-28),
7. 7375120 - Peptide deformylase inhibitors (2008-05-20),
8. 7332485 - Peptide deformylase inhibitors (2008-02-19),
9. 7166624 - Peptide deformylase inhibitors (2007-01-23),
10. 7115605 - Peptide deformylase inhibitors (2006-10-03),
11. 7019003 - Peptide deformylase inhibitors (2006-03-28),
12. 6967220 - Peptide deformylase inhibitors (2005-11-22),
13. 6897233 - Peptide deformylase inhibitors (2005-05-24),
14. 6852882 - Peptide deformylase inhibitors (2005-02-08),
15. 6806369 - Peptide deformylase inhibitors (2004-10-19),

Title: The Innovative Journey of Siegfried B Christensen IV

Introduction:

Siegfried B Christensen IV is a prolific inventor based in Philadelphia, PA, with an impressive portfolio of 63 patents to his credit. His groundbreaking work has made a significant impact on various fields, particularly in the realm of pharmaceuticals and healthcare.

Latest Patents:

Among his latest patents, Christensen has developed compounds that serve as diacylglycerol acyltransferase inhibitors. These novel compounds play a crucial role in inhibiting acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), offering therapeutic solutions for a range of diseases such as obesity, hyperlipoproteinemia, diabetes, and skin disorders. Additionally, he has pioneered peptide deformylase inhibitors, revolutionizing the field of PDF inhibitors with novel methods for their application.

Career Highlights:

Christensen's innovative spirit and dedication have been showcased through his tenure at renowned companies such as SmithKline Beecham Corporation and Glaxo Group Limited. His contributions to these organizations have been instrumental in driving forward advancements in pharmaceutical research and development.

Collaborations:

Throughout his career, Christensen has collaborated with esteemed professionals like Joseph M Karpinski and Paul E Bender. These partnerships have led to the creation of groundbreaking inventions and have strengthened the foundation of innovation in the industry.

Conclusion:

In conclusion, Siegfried B Christensen IV stands as a trailblazing inventor whose work has transformed the landscape of pharmaceuticals and healthcare. His pioneering patents and collaborative efforts underscore his commitment to driving progress and innovation in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…